BNP Paribas Financial Markets
VTAE

BNP Paribas Financial Markets’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

BNP Paribas Financial Markets’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,878
Closed -$39.3K – 4268
2016
Q3 		$39.3K Buy
1,878
+853
+83% +$9.82K ﹤0.01% 2540
2016
Q2 		$11.1K Buy
1,025
+861
+525% +$7.36K ﹤0.01% 2866
2016
Q1 		$1.09K Sell
164
-2,454
-94% -$22.3K ﹤0.01% 2496
2015
Q4 		$47.4K Sell
2,618
-480
-15% -$6.61K ﹤0.01% 2844
2015
Q3 		$34.1K Buy
3,098
+1,994
+181% +$21.2K ﹤0.01% 3107
2015
Q2 		$15.9K Buy
1,104
+960
+667% +$13K ﹤0.01% 3190
2015
Q1 		$1.69K Buy
+144
New +$1.94K ﹤0.01% 3499

BNP Paribas Financial Markets's VTAE Position: Q4 2016 in Review

BNP Paribas Financial Markets sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 1,878 shares — an estimated $39.3K sold.

BNP Paribas Financial Markets first reported a position in VTAE in Q1 2015 and held it in 7 quarters. The position peaked at $47.4K in Q4 2015. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

  • BNP Paribas Financial Markets reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,878 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $39.3K.
  • BNP Paribas Financial Markets first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015 and held it in 7 quarters.
  • BNP Paribas Financial Markets's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $47.4K in Q4 2015.
  • 0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2016, filed 14 Feb 2017.